Issue 45, 2024, Issue in Progress

Identification of new leads against ubiquitin specific protease-7 (USP7): a step towards the potential treatment of cancers

Abstract

Ubiquitin-specific protease-7 (USP7) is an important drug target as it regulates multiple proteins and genes (such as MDM2 and p53) with roles in cancer progression. Its inhibition can hinder the function of oncogenes, increase tumor suppression, and enhance immune response. The current study was designed to express USP7 in a prokaryotic system, followed by screening of small molecules against it using biophysical methods, primarily STD-NMR technique. Among them, 12 compounds showed interaction with USP7 as inferred from NMR-based screening. These compounds further caused destabilization of USP7 by reducing its melting temperature (Tm) up to 6 °C in thermal shift assay. Molecular docking and simulation studies revealed that these compounds bind to the putative substrate binding pocket of USP7 and thus may block the entry of the substrate. Four compounds i.e., 4-hydroxy-diphenyl amine (2), phenyl-(2,3,4-trihydroxyphenyl) methanone (3), 4′-amino-2′,5′-diethoxy benzanilide (5), and hydroquinone (12), showed anti-cancer activity against colorectal cancerous cells (HCT116) with IC50 values in the range of 31–143 μM. These compounds also down-regulated the mRNA expression of the MDM2 gene and up-regulated the mRNA expression of the p53 gene in HCT116 cells, as studied using qPCR analysis. This study thereby identifies several negative modulators of USP7 that can be studied further as potential anti-cancer agents.

Graphical abstract: Identification of new leads against ubiquitin specific protease-7 (USP7): a step towards the potential treatment of cancers

Supplementary files

Article information

Article type
Paper
Submitted
21 Sep 2024
Accepted
07 Oct 2024
First published
21 Oct 2024
This article is Open Access
Creative Commons BY-NC license

RSC Adv., 2024,14, 33080-33093

Identification of new leads against ubiquitin specific protease-7 (USP7): a step towards the potential treatment of cancers

S. Javaid, S. Zadi, M. Awais, A. Wahab, H. Zafar, I. Maslennikov and M. I. Choudhary, RSC Adv., 2024, 14, 33080 DOI: 10.1039/D4RA06813K

This article is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported Licence. You can use material from this article in other publications, without requesting further permission from the RSC, provided that the correct acknowledgement is given and it is not used for commercial purposes.

To request permission to reproduce material from this article in a commercial publication, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party commercial publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements